Injectable Clostridium difficile spores lyophilized powder is currently in the interim experimental period, has not been formally marketed, the specific use of dosage is not clear.
The main active ingredient of Clostridium difficile lyophilized powder for injection is Clostridium difficile spores, and Clostridium difficile is a specialized anaerobic bacillus of the genus Clostridium, whose spores can remain active in an oxygen-rich environment, but cannot germinate into bacteria.
Its spores can remain active in an oxygen-rich environment, but cannot germinate into bacteria. Clostridium difficile spores can germinate into bacteria only when they enter into the anoxic and necrotic area of solid tumors, and they can colonize and proliferate in the anoxic and necrotic area of tumors, constantly seize and deprive the tumor cells of raw materials, energy, and space, etc., so as to inhibit the growth of the tumor cells, and dissolve the tumor tissues efficiently and indistinguishably.
Therefore, the specific dosage of Clostridium perfringens lyophilized powder can only be clarified after the clinical trial period, and the above information is for reference only. To summarize, this drug is still in the clinical trial stage, there are finished products but only for clinical trials, to be evaluated after the efficacy and safety can be marketed, so in the Clostridium Gossypii Spores Lyophilized Powder clinical trial period before the specific dosage.